标题
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 22, Pages 5792
出版商
MDPI AG
发表日期
2019-11-18
DOI
10.3390/ijms20225792
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Overgrowth syndromes — clinical and molecular aspects and tumour risk
- (2019) Frédéric Brioude et al. Nature Reviews Endocrinology
- New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives
- (2019) A. Mühlebner et al. JOURNAL OF ANATOMY
- PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
- (2019) Vaishnavi Sambandam et al. CLINICAL CANCER RESEARCH
- The “other” mTOR complex: New insights into mTORC 2 immunobiology and their implications
- (2019) Helong Dai et al. AMERICAN JOURNAL OF TRANSPLANTATION
- First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma
- (2019) Chiara Leoni et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Targeting PI3K signaling in cancer: Challenges and advances
- (2019) Maria Chiara De Santis et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review
- (2019) Mahnaz Jamee et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia
- (2019) Anna M Frustaci et al. Future Oncology
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
- (2019) Franziska Maria Ippen et al. NEURO-ONCOLOGY
- The PTEN–PI3K Axis in Cancer
- (2019) Papa et al. Biomolecules
- MicroRNA‑21‑5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma
- (2019) Changfu Liu et al. Experimental and Therapeutic Medicine
- Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex
- (2018) Young In Lee et al. DERMATOLOGY
- 65 YEARS OF THE DOUBLE HELIX: One gene, many endocrine and metabolic syndromes: PTEN -opathies and precision medicine
- (2018) Lamis Yehia et al. ENDOCRINE-RELATED CANCER
- Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures
- (2018) David N. Franz et al. EPILEPSIA
- Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review
- (2018) Isra’ Zeiadeh et al. MOLECULES
- Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy
- (2018) E. Marsan et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex
- (2018) Mary Kay Koenig et al. JAMA Dermatology
- Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy
- (2018) David Michalovich et al. Frontiers in Immunology
- Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma
- (2018) Guiqin Hou et al. BIOMEDICINE & PHARMACOTHERAPY
- Targeted therapy in patients with PIK3CA-related overgrowth syndrome
- (2018) Quitterie Venot et al. NATURE
- The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
- (2018) Claudia Brandt et al. NEUROPHARMACOLOGY
- Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer
- (2018) Francoise Borson-Chazot et al. THYROID
- Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
- (2018) Ralitsa R. Madsen et al. TRENDS IN MOLECULAR MEDICINE
- Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
- (2018) Denise Rageot et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
- (2017) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing
- (2017) Paul Kuentz et al. GENETICS IN MEDICINE
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells
- (2017) Russell G. Jones et al. IMMUNITY
- Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development
- (2017) Anna Jeong et al. JOURNAL OF CHILD NEUROLOGY
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
- (2017) Hua-fu Zhao et al. Molecular Cancer
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
- (2017) Klemens Hoegenauer et al. ACS Medicinal Chemistry Letters
- Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
- (2017) Thomas Bohnacker et al. Nature Communications
- CC-115, a dual inhibitor of mTOR Kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
- (2017) Toshiya Tsuji et al. Oncotarget
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts
- (2017) Maria De Santis et al. Cancers
- TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia
- (2016) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nephroblastomatosis or Wilms tumor in a fourth patient with a somaticPIK3CAmutation
- (2016) Karen W. Gripp et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
- (2016) Kim M. Keppler-Noreuil et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- Brain somatic mutations in MTOR leading to focal cortical dysplasia
- (2016) Jae Seok Lim et al. BMB Reports
- Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
- (2016) I. A. Netland et al. BMC CANCER
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.
- (2016) T.C. Schneider et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- (2016) Jacqueline A French et al. LANCET
- Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K and PI3K , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
- (2016) K. Hudson et al. MOLECULAR CANCER THERAPEUTICS
- Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement
- (2016) Lawrence S. Hsieh et al. Nature Communications
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Association ofMTORMutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
- (2016) Ghayda M. Mirzaa et al. JAMA Neurology
- Tuberous sclerosis complex
- (2016) Elizabeth P. Henske et al. Nature Reviews Disease Primers
- Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulatorNPRL3
- (2015) Joe C. Sim et al. ANNALS OF NEUROLOGY
- A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
- (2015) Johanna C. Bendell et al. CANCER
- Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma
- (2015) Bing Zheng et al. CANCER LETTERS
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
- (2015) S. M. Guichard et al. MOLECULAR CANCER THERAPEUTICS
- Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model
- (2015) Shilpa Prabhakar et al. NEUROBIOLOGY OF DISEASE
- Clinical delineation and natural history of thePIK3CA-related overgrowth spectrum
- (2014) Kim M. Keppler-Noreuil et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Focal dysplasia of the cerebral cortex and infantile spasms associated with somatic 1q21.1-q44 duplication including theAKT3gene
- (2014) V. Conti et al. CLINICAL GENETICS
- An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2
- (2014) Kameswaran Ravichandran et al. HUMAN MOLECULAR GENETICS
- Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
- (2014) P. Yu et al. MOLECULAR CANCER THERAPEUTICS
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
- (2013) Darcy A. Krueger et al. ANNALS OF NEUROLOGY
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
- (2013) Michael Wong Biomedical Journal
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
- (2012) J. M. Spoerke et al. CLINICAL CANCER RESEARCH
- Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
- (2012) Marjorie J Lindhurst et al. NATURE GENETICS
- Targeted therapy in rare cancers—adopting the orphans
- (2012) Javier Munoz et al. Nature Reviews Clinical Oncology
- Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations
- (2012) Annapurna Poduri et al. NEURON
- Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection
- (2012) Kevin A. Kwei et al. PLoS One
- Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis
- (2011) Nicole A. Neuman et al. EMBO Molecular Medicine
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)
- (2010) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis
- (2009) P Bonifazi et al. Mucosal Immunology
- Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
- (2008) Ling-Hui Zeng et al. ANNALS OF NEUROLOGY
- A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
- (2008) Neil E. Torbett et al. BIOCHEMICAL JOURNAL
- Reversal of learning deficits in a Tsc2 +/− mouse model of tuberous sclerosis
- (2008) Dan Ehninger et al. NATURE MEDICINE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started